NCT01606761 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy Posted on June 6, 2018 by tsuperadmin -
NCT01604343 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy Posted on June 6, 2018 by tsuperadmin -
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Posted on April 12, 2018 by tsuperadmin -
NCT01985126 – An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD Posted on March 22, 2018 by tsuperadmin -
Phase II clinical trial of ET-743 as 2nd or 3rd line treatment in patients with advanced stage and/or metastatic soft tissue sarcoma Posted on March 15, 2018 by tsuperadmin -
NCT00796120 – An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Posted on March 15, 2018 by tsuperadmin -
NCT00579501 – Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Posted on March 15, 2018 by tsuperadmin -
Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients Posted on March 15, 2018 by tsuperadmin -
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients Posted on March 15, 2018 by tsuperadmin -
Phase II study on ET-743 in advanced soft tissue sarcomas of the adult (excluding gastrointestinal stroma cell tumors – GIST) Posted on March 15, 2018 by tsuperadmin -
The YODA Project